Table 2.

Persistence in new users of tofacitinib and bDMARD.

 Discontinued/Switched During Follow-up, n (%)Median PersistenceHR (Tofacitinib to the bDMARD)
CrudeAdjusted
Tofacitinib, n = 1031591 (57.3)0.81 (0.73–0.91)NANA
bDMARD, n = 17,8039338 (52.5)1.02 (0.99–1.05)1.18 (1.09–1.28)1.14 (1.05–1.25)
Adalimumab, n = 60073213 (53.5)1.00 (0.94–1.06)1.17 (1.07–1.28)1.13 (1.03–1.24)
Certolizumab pegol, n = 646404 (62.5)0.67 (0.57–0.77)0.87 (0.76–0.98)0.84 (0.74–0.96)
Etanercept, n = 65583416 (52.1)1.03 (0.99–1.09)1.19 (1.09–1.30)1.17 (1.07–1.28)
Golimumab, n = 751370 (49.3)1.18 (0.92–1.40)1.34 (1.18–1.53)1.31 (1.14–1.49)
Infliximab, n = 1597754 (47.2)1.42 (1.23–1.67)1.43 (1.28–1.59)1.37 (1.22–1.53)
Abatacept, n = 1641854 (52.0)0.93 (0.82–1.10)1.10 (0.99–1.22)1.08 (0.97–1.20)
Tocilizumab, n = 603327 (54.2)0.82 (0.69–0.96)0.97 (0.85–1.11)0.96 (0.84–1.10)
  • HR for discontinuation (95% CI), where the bDMARD is the reference. Values < 1 favor tofacitinib (i.e., longer persistence with tofacitinib).

  • Median persistence (95% CI) estimated in years using Kaplan-Meier methodology. bDMARD: biological disease-modifying antirheumatic drug; NA: not applicable.